PMC2825242_01
Location of (A) the carcinoid tumor in the verumontanum of the prostatic urethra; and (B) the prostatic adenocarcinoma within the prostate at the right posterior lobe of the prostate. These consecutive whole prostatectomy slices were sectioned 5 mm apart and the tumors appear to be located at approximately 17 mm from each other. Hematoxylin-eosin staining (scanned slides with Aperio system).
1752-1947-4-16-1.jpg
PMC2825242_01_1752-1947-4-16-1.jpg
F1
A single focus of invasive, variably spaced, small atypical acinar glands without basal cells was identified in the periphery of the mid-left, posterior quadrant of the prostate, involving less than 5% of the prostatic tissue (Figure 1).
(A) Carcinoid tumor (40x objective), (B) and C) prostatic adenocarcinoma Gleason grade 3 + 3 (sum = 6) (10x & 40x objectives). Hematoxylin-eosin staining.
1752-1947-4-16-2.jpg
PMC2825242_01_1752-1947-4-16-2.jpg
F2
The cytologic features were consistent with prostatic adenocarcinoma and included enlarged and overlapping nuclei with prominent and peripherally marginated nucleoli (Figures 2Band 2C). Higher power examination revealed cells forming nested, acinar and trabecular architecture with small uniform nuclei, a granular "salt and pepper" chromatin pattern, and moderate amounts of granular cytoplasm (Figure 2A).
Carcinoid tumor of the veramontanum (colliculus seminalis) of the prostatic urethra, hematoxylin-eosin staining (2x objective).
1752-1947-4-16-3.jpg
PMC2825242_01_1752-1947-4-16-3.jpg
F3
From low microscopic power, the tumor of our patient appeared well circumscribed with pushing, rather than invasive, margins (Figure 3).
Immunoperoxidase staining for chromogranin A (20x) (A), neuron specific enolase (B) and synaptophysin (C) of the carcinoid tumor cells (40x objective).
1752-1947-4-16-4.jpg
PMC2825242_01_1752-1947-4-16-4.jpg
F4
Immunoperoxidase staining for chromogranin A, neuron specific enolase, and synaptophysin were positive in nearly 100% of the urethral tumor cells, showing a granular cytoplasmic distribution (Figure 4).